Jupiter Neurosciences Inc (JUNS)

JUNS...................https://stockcharts.com/sc3/ui/?s=JUNS&p=w&b=5&g=0&id=p86431144783

D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct OfferingMay 26, 2026 12:00 PM
ACCESS NewswireNEW YORK CITY, NY / ACCESS Newswire / May 26, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, closed its securities purchase agreement for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering. The gross proceeds of the offering are approximately $2.0 million (the "Offering").D. Boral Capital LLC acted as the Exclusive Placement Agent for the Offering.The shares of common stock were offered by the Company pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-295085), which was declared effective by the U.S. Securities and Exchange Commission (the "SEC") on April 24, 2026.A prospectus supplement describing the terms of the proposed registered direct offering was filed with the SEC. Once filed, it was available on the SEC's website at http://www.sec.gov. A copy of the prospectus supplement and accompanying base prospectus relating to the offering may be obtained from D. Boral Capital LLC, 590 Madison Avenue, 39th Floor, New York, NY 10022, or by telephone at (212) 404-7002, or by email at dbccapitalmarkets@dboralcapital.com.This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About Jupiter Neurosciences, Inc.Jupiter Neurosciences, Inc. (NASDAQ:JUNS) is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. The Company's lead program, JOTROL(TM) -- a proprietary, enhanced bioavailability resveratrol formulation -- is currently in a Phase IIa clinical trial for Parkinson's disease. JUNS also commercializes Nugevia (TM), a consumer longevity supplement. The acquisition of ALA-002 U.S. rights further strengthens the Company's CNS pipeline by adding a next-generation, patented psychedelic NCE at a pivotal moment in U.S. regulatory policy. For more information, please visit www.jupiterneurosciences.com.About D. Boral CapitalD. Boral Capital LLC is a premier, relationship-driven global investment bank headquartered in New York. The firm is dedicated to delivering exceptional strategic advisory and tailored financial solutions to middle-market and emerging growth companies. With a proven track record, D. Boral Capital provides expert guidance to clients across diverse sectors worldwide, leveraging access to capital from key markets, including the United States, Asia, Europe, the Middle East, and Latin America.A recognized leader on Wall Street, D. Boral Capital has successfully aggregated approximately $35 billion in capital since its inception in 2020, executing ~400 transactions across a broad range of investment banking products.D. Boral Capital is a member of FINRA and SIPC.Forward-Looking StatementsStatements made in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are often indicated by terms such as "aim," "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "likely," "look forward to," "may," "objective," "plan," "potential," "predict," "project," "should," "slate," "target," "will," "would" and similar expressions and variations thereof. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Jupiter's actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in our Annual Report on Form 10-K filed on April 1, 2026. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.For more information, please contact:Investor Relations Contact
Jupiter Neurosciences, Inc.
Christer Rosen, Chairman & Chief Executive Officer
ir@jupiterneurosciences.comD. Boral Capital LLC
Email: dbccapitalmarkets @Tin-BerrygoodSOURCE: D. Boral CapitalView the original press release on ACCESS NewswireOriginal: D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering

JUNS...............................p/m

Key Investor Takeaway

JUNS to Dilute

PharmAla Biotech Signs Term Sheet for $100 Million U.S. Licensing Deal for ALA-002 MDMA Therapy (MDXXF)May 20, 2026 11:12 AM
IH Market News The proposed agreement would grant Jupiter Neurosciences exclusive U.S. rights to PharmAla’s lead psychedelic drug candidate while allowing PharmAla to retain international commercialization rights. Key Investor Takeaways PharmAla Biotech (USOTC:MDXXF) signed a term sheet to license exclusive U.S. rights to its ALA-002 MDMA therapeutic candidate to Jupiter Neurosciences (NASDAQ:JUNS). The proposed transaction carries a potential value exceeding $100 million through upfront payments, milestone payments, and royalties. ALA-002 is positioned as a next-generation non-racemic MDMA therapy with FDA-recognized Novel Chemical Entity status. PharmAla would retain all ex-U.S. rights, including its Australian commercial operations through the Cortexa joint venture. The agreement remains subject to due diligence, definitive agreements, financing, and regulatory approvals. Why MDXXF Stock Is in Focus PharmAla Biotech announced that it entered into a term sheet with Jupiter Neurosciences covering exclusive perpetual U.S. licensing rights for ALA-002, the company’s lead MDMA-based drug candidate.Under the proposed structure, PharmAla would receive upfront consideration totaling approximately $3.33 million at closing, including $1.50 million in cash and $1.83 million in Jupiter common stock.The term sheet also outlines additional milestone payments and single-digit royalties tied to future development, regulatory approval, and commercialization milestones.Jupiter has additionally agreed to place $600,000 into escrow upon signing of the term sheet. If a definitive agreement is not completed within 90 days, PharmAla would retain the escrow amount as a reverse termination fee, subject to specified exceptions.ALA-002 is described as a patented non-racemic MDMA formulation recognized by the FDA as a Novel Chemical Entity.According to the company, the therapy was engineered to improve cardiovascular safety and reduce abuse liability while maintaining therapeutic properties associated with MDMA-assisted treatment.PharmAla also stated that its clinical-grade MDMA products are currently being supplied into multiple U.S. government-sponsored clinical trials, including studies funded by the Department of Veterans Affairs and the Defense Health Agency. Why This Matters for Investors The proposed licensing transaction may represent a significant strategic milestone for PharmAla because it could provide external validation of the company’s intellectual property and development strategy around next-generation psychedelic therapeutics.For investors, the structure allows PharmAla to potentially monetize U.S. commercialization rights while retaining long-term exposure to international markets and future royalty streams.The deal may also strengthen the company’s balance sheet through upfront non-dilutive capital while adding an equity stake in a NASDAQ-listed biotechnology company.The focus on ALA-002’s FDA-recognized Novel Chemical Entity status could become important as companies within the psychedelic therapeutics sector attempt to differentiate proprietary formulations from generic psychedelic compounds.At the same time, investors may continue to monitor execution risk. The proposed transaction has not yet closed and remains subject to due diligence, definitive agreements, financing considerations, and regulatory approvals.The broader commercialization pathway for psychedelic-assisted therapies also remains highly dependent on evolving regulatory frameworks and clinical development outcomes. What to Watch Next Investors will likely monitor: Whether definitive agreements are finalized within the 90-day term sheet period Additional development timelines for ALA-002 Regulatory and clinical progress tied to MDMA-assisted therapies Future milestone payment structures and royalty terms Commercial expansion updates involving Cortexa in Australia Any additional partnerships or licensing transactions tied to PharmAla’s MDXX pipeline Financing and strategic updates from Jupiter Neurosciences (NASDAQ:JUNS) PharmAla Biotech Holdings stock price Original: PharmAla Biotech Signs Term Sheet for $100 Million U.S. Licensing Deal for ALA-002 MDMA Therapy (MDXXF)

$JUNS: Added 50k here at $0.34...........

Nice dip back.......... gimme minimum $0.50 now


GO $JUNS

JUNS................................https://stockcharts.com/sc3/ui/?s=JUNS&p=W&b=5&g=0&id=p86431144783

Jupiter Neurosciences, Inc. to Present at The Market Movers Investor SummitMay 4, 2026 11:30 AM
NewsfileJupiter, Florida--(Newsfile Corp. - May 4, 2026) - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, announced today that it will be participating in the Market Movers Investor Summit on Tuesday May 5, 2026. The presentation will take place at 09:00 AM ET at the historic Bank of New York. Christer Rosén, Chairman and CEO, will be giving the presentation.The Market Movers Investor Summit is a premier, high-access event on Wall Street. The Inaugural program features fireside chats with Alex Rodriguez, Chairman and CEO of A-Rod Corp, and Grant Cardone, CEO of Cardone Capital, in addition to company presentations and one-on-one meetings throughout the day.Event Details:Summit Dates: May 5, 2026 Company Presentation: Tuesday, May 5, 2026 Time: 09:00 AM ET Location: 48 Wall Street, New York, NY (The original Bank of New York)Request an invitation to attend at www.marketmoverssummit.com.Summary of Market Movers Investor SummitThe 2026 Market Movers Investor Summit begins on May 4th with a kickoff party at the legendary Delmonico’s, followed by a full day of programming on May 5th. The summit brings together public and private company executives, fund managers, and family offices for a focused, high-caliber experience. The agenda includes company presentations, exclusive fireside chats and keynote sessions, a pop-up lunch from the legendary Katz Delicatessen and a surprise musical guest.About Jupiter Neurosciences, Inc.Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia™ product line. Both efforts are powered by JOTROL™, Jupiter's proprietary, enhanced resveratrol formulation that has demonstrated improved bioavailability in clinical studies. The Company's prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson's disease, including indications such as Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS.About Market MoversMarket Movers is a next-generation investor conference designed for people responsible for capital, growth, and strategic outcomes. Hosted on Wall Street inside the original Bank of New York, the event brings together public & company leaders, investors, real estate principals, founders, and operators for a focused, high-access experience. The emphasis is on meaningful conversations, real connections, and perspectives that extend beyond a single market or asset class.To learn more about the Market Movers Investor Summit, visit:
https://www.marketmoverssummit.comFor further information on Jupiter Neurosciences, Inc.
Christer Rosén
(561) 406-6154
ir@jupiterneurosciences.com
https://jupiterneurosciences.com
Original: Jupiter Neurosciences, Inc. to Present at The Market Movers Investor Summit

Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14April 13, 2026 8:00 PM
NewsfileJupiter, Florida--(Newsfile Corp. - April 13, 2026) - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, will present at the Centri Capital Conference on Tuesday, April 14 at Nasdaq in New York City.Christer Rosén, Chairman and CEO will discuss the Company's recent performance and future growth plans. The Centri Capital Conference will gather attendees from across the capital markets ecosystem and investment community, including investment bankers, private equity investors, family offices, and high-net-worth individuals. The highly anticipated conference will feature company presentations and fireside chats, facilitated investor 1:1 meetings, and panel discussions featuring insights from thought leaders in the capital markets space.Jupiter Neurosciences, Inc. joins a distinguished list of exciting and disruptive presenting companies like Grayscale, Orchestra BioMed, CoinShares, ReserveOne, MVB Financial and many others. Also included in the event at Nasdaq are key sponsors in the capital markets space, including Morgan Stanley, DFIN, Chardan, Gusto, CBIZ, ICR and The Money Channel."The companies involved with the Centri Capital Conference embody the innovation and diversity shaping today’s capital markets,” says Michael Aiello, CEO & Managing Partner of Centri. “We are excited to welcome them to Nasdaq for investor 1:1 meetings and meaningful exchanges with leaders from across the industry."Companies and investors interested in presenting, attending, or sponsoring the Centri Capital Conference can learn more here: www.CentriConsulting.com/capital-conference. About Jupiter Neurosciences, Inc.Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia™ product line. Both efforts are powered by JOTROL™, Jupiter's proprietary, enhanced resveratrol formulation that has demonstrated improved bioavailability in clinical studies. The Company's prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson's disease, including indications such as Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS.About Centri Business Consulting, LLCCentri Business Consulting provides the highest quality advisory consulting services to its clients by being reliable and responsive to their needs. Centri provides companies with the expertise they need to meet their reporting demands. Centri specializes in financial reporting, internal controls, technical accounting research, valuation, mergers & acquisitions, and tax, CFO and HR advisory services for companies of various sizes and industries. From complex technical accounting transactions to monthly financial reporting, our professionals can offer any organization the specialized expertise and multilayered skillsets to ensure the project is completed timely and accurately.For additional Information, please contact:Jupiter Neurosciences, Inc.
Christer Rosén
(561) 406-6154
ir@jupiterneurosciences.com
https://jupiterneurosciences.com/
Original: Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14

Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery ConferenceJanuary 27, 2026 3:45 PM
ACCESS NewswireJUPITER, FL / ACCESS Newswire / January 27, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform for neuroinflammation and healthy aging, today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026.Christer Rosén, Chairman and CEO of Jupiter Neurosciences, will deliver a company presentation and be available for one-on-one investor meetings throughout the event. Learn more about Jupiter Neurosciences at www.jupiterneurosciences.com.Event Details:Conference: 3rd Annual DealFlow Discovery ConferenceVenue: The Borgata Hotel, Casino & SpaLocation: Atlantic City, NJDate: January 28-29, 2026Investors interested in scheduling a meeting with the Jupiter Neurosciences management team should request an investor pass to attend the conference (no cost to attend).About Jupiter Neurosciences, Inc.Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line. Both efforts are powered by JOTROL™, Jupiter's proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company's prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson's disease, including indications such as Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS.Media Contact:Christer Rosén
Chairman and CEO
Jupiter Neurosciences, Inc.
IR@jupiterneurosciences.comSOURCE: DealFlow EventsView the original press release on ACCESS NewswireOriginal: Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference

Jupiter Neurosciences (Nasdaq: JUNS) Investor Webinar - January 6, 2026



Weekly Chart
https://schrts.co/QFyyXIHS

$JUNS Jupiter Neurosciences: Advancing World-Class Neuro Therapies with $50B+ Market Potential

$50B+ Longevity Opportunity: $JUNS Jupiter Neurosciences CEO Christer Rosen & President Alison Silva, Live at Nasdaq https://finance.yahoo.com/news/50b-longevity-opportunity-jupiter-neurosciences-192916920.html

" Strengthening Foundation in $8 Trillion Longevity Market

In 2025, Jupiter launched Nugevia, a premium longevity supplement line designed to generate near-term revenue while elevating our brand visibility and deepening the market’s understanding of our science.

Nugevia’s three launch products — GLO, PWR, and MND — each integrate our patented JOTROL™ platform with synergistic, highly bioavailable ingredients such as NovaSOL® Astaxanthin, CoQ10, and Curcumin to support skin vitality, mitochondrial energy, and cognitive resilience. Together, they deliver pharmaceutical-grade standards into a consumer market projected to exceed $8 trillion by 2030.

$JUNS FDA Clears IND to Initiate Phase 2a Trial in Parkinson’s Disease

In November 2025, the U.S. FDA officially cleared our IND application, authorizing Jupiter to initiate a Phase 2a clinical trial of JOTROL™ in Parkinson’s disease, a critical regulatory milestone that positions us to begin patient enrollment in early 2026.

This milestone is the culmination of years of scientific development and validation demonstrating JOTROL’s nine-fold bioavailability improvement, blood-brain barrier penetration, and compelling neuroprotective effects in the well-established MPTP Parkinson’s model. With Zina Biopharmaceuticals guiding trial protocol and biomarker strategy, and Catalent as our manufacturing partner, we enter 2026 fully prepared to advance this landmark study.

$JUNS News : Jupiter Neurosciences Marks Transformational First Year as a Public Company, Entering 2026 with Powerful Clinical and Commercial Momentum
Company advances JOTROL™ into Phase 2a Parkinson’s trial, launches Nugevia™ consumer brand, and strengthens financial position

Jupiter, Florida, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced the publication of a shareholder letter from Chairman and CEO Christer Rosén marking Jupiter’s first full year as a public company and outlining the major achievements and strategic priorities propelling the Company into 2026.
https://finance.yahoo.com/news/jupiter-neurosciences-marks-transformational-first-130000175.html

$JUNS Analyst Report
Jupiter announced a partnership with Aquanova AG to develop a series of nutritional products targeting longevity, aging and healthspan. The first three products, which will focus on the concept of “Beauty from Within”, are slated to hit the market in Q3:25 through a Direct-to-Consumer model.

Investor Presentation https://www.redchip.com/stocks/JUNS

Exciting news from the biotech world! Jupiter Neurosciences, Inc. ( $JUNS on #NASDAQ), a clinical-stage pharmaceutical company focused on addressing neuroinflammation and promoting healthy aging, has just received #FDA Clearance for its IND application to kick off a Phase 2a clinical trial of #JOTROL™ in Parkinson’s disease.

$JUNS POTENTIAL EXPANSION : JUNS STOCK ANALYSIS | JUPITER NEUROSCIENCES INC STOCK

Jupiter Neurosciences, #JUNS on #NASDAQ, just received #FDA Clearance for its IND application JOTROL

Jupiter Neurosciences, Inc. (Nasdaq: JUNS) is a clinical-stage pharmaceutical company pioneering treatments for neuroinflammation and rare diseases through its proprietary resveratrol delivery platform. Its lead product, JOTROL™, offers groundbreaking bioavailability—nine times greater than traditional resveratrol formulations—enabling safe, effective treatment for CNS disorders like Alzheimer's and Parkinson's. Backed by elite research partnerships and a robust clinical pipeline, including multiple Phase 2 trials expected to launch within the next 12 months, Jupiter is also advancing a near-term direct-to-consumer revenue opportunity in nutraceuticals, positioning the company as a transformative force in both pharmaceutical and consumer health markets.

$JUNS News : Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing
https://finance.yahoo.com/news/jupiter-neurosciences-enters-agreements-20-123000514.html

#JUNS #NASDAQ Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease



https://finance.yahoo.com/news/jupiter-neurosciences-receives-fda-clearance-133000472.html

$JUNS Jupiter Neurosciences, Inc. (JUNS) Price Targets https://zacks.com/stock/research/ONCY/price-target-stock-forecast

$JUNS - Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease


https://finance.yahoo.com/news/jupiter-neurosciences-receives-fda-clearance-133000472.html

JUNS...$2.96...🥳...Off my $1.20 Alert...

georgie18

Member Level
Re: georgie18 post# 394548

Monday, July 14, 2025 3:45:23 PM

Post#
395415
of 395477
JUNS...$2.73...🥳...Off my $1.20 Alert...

georgie18

Member Level
Re: None

Wednesday, June 18, 2025 3:30:10 PM

Post#
13
of 15
JUNS...$1.20...🥳...Reversal Candle...off the .90 range bottom...

JUNS...$2.73...🥳...Off my $1.20 Alert...

georgie18

Member Level
Re: None

Wednesday, June 18, 2025 3:30:10 PM

Post#
13
of 15
JUNS...$1.20...🥳...Reversal Candle...off the .90 range bottom...

$JUNS 💹

Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery

https://www.globenewswire.com/news-release/2025/06/30/3107830/0/en/Jupiter-Neurosciences-Showcases-Nugevia-PWR-Mitochondrial-Optimization-Supplement-Designed-to-Boost-Energy-Endurance-and-Recovery.html

=================

Jupiter Neurosciences Unveils Nugevia™ GLO: A Breakthrough in Cellular Skin Health, Backed by Patented Pharmaceutical Science

https://finance.yahoo.com/news/jupiter-neurosciences-unveils-nugevia-glo-120000709.html?guccounter=1&guce_referrer=aHR0cHM6Ly9kdWNrZHVja2dvLmNvbS8&guce_referrer_sig=AQAAAJeEVM9KLf4BVOujCNJY4jlBJmM4tD5WPFb25DnQFZS3bgnJFwcGVfcTXi8nFBeqKrWBz93daRnaSg5yVjbnJSI5sfo29CC5TfufUj-cy9WTcbqheU4ieJ-fVgN7D-dSo_WNfeiecUj2rYD_2rKf59CwTTeNZKMvphI55fTXEziZ

=================

Jupiter Neurosciences to launch mitochondrial health supplement this fall

https://www.investing.com/news/company-news/jupiter-neurosciences-to-launch-mitochondrial-health-supplement-this-fall-93CH-4117651

=================

About Jupiter Neurosciences, Inc.
Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia™ product line. Both efforts are powered by JOTROL™, Jupiter’s proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company’s prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson’s disease, includeing indications such as Alzheimer’s Disease, Mucopolysaccharidoses Type I, Friedreich’s Ataxia, and MELAS. More information may be found on the Company’s website www.jupiterneurosciences.com.

$JUNS 💹

JUNS...$1.20...🥳...Reversal Candle...off the .90 range bottom...

JUNS is running a promotion. Currently being touted by "RedChip" on Bloomberg TV. 

Back down to $11 halt 38% 

JUNS: WHERE do you see that 120%??? Is that your price TARGET??? (Etrade, etc.,.shows only 38%.)

$17 +120%

JUNS: O.K., sounds fine to me, Homeboy!!

From Saturn off to Jupiter $11.79 + 50%

JUNS (IPO):

$JUNS: IPO is launching next week

We are waiting on it.



Jupiter Neurosciences, Inc. has developed the first and only resveratrol product that safely reaches therapeutic levels without GI-side effects creating treatment possibilities in many indications.

https://jupiterneurosciences.com/








GO $JUNS

JUNS: Evidently, now ready-to-go on E-Turd, Fidelity, etc.

Ticker hasn’t shown up on E*TRADE yet

IPO scheduled for February 3, 2022.

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer’s disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.